Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-022-02155-3
Abstract: This all-case post-marketing surveillance (PMS) evaluated the real-world safety and effectiveness of nivolumab monotherapy in Japanese patients with un-resectable or metastatic renal cell carcinoma (RCC). This multicenter, open-label, non-interventional, observational PMS study (registered from August… read more here.
Keywords: safety effectiveness; post marketing; marketing surveillance; real world ... See more keywords
Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2022.2062322
Abstract: ABSTRACT Background Empagliflozin, a glucose-lowering drug licensed for type 2 diabetes (T2D), demonstrated tolerability and effectiveness overall in a post-marketing surveillance (PMS) study in Japan. However, the impact of body mass index (BMI) is unclear.… read more here.
Keywords: body mass; marketing surveillance; type diabetes; post marketing ... See more keywords
Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.13012
Abstract: To evaluate linagliptin prescribing in type 2 diabetes mellitus patients with different comorbidities, an expanded Japanese post‐marketing surveillance also collected baseline data for patients initiating other glucose‐lowering drugs. read more here.
Keywords: type diabetes; linagliptin; post marketing; marketing surveillance ... See more keywords
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT)
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.13333
Abstract: Tofogliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor that lowers plasma glucose levels by enhancing urinary glucose excretion. After its approval in Japan in 2014 for the treatment of type 2 diabetes mellitus, we carried… read more here.
Keywords: japanese patients; surveillance study; type diabetes; diabetes mellitus ... See more keywords
Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1134436
Abstract: Although the immunotherapy advent has revolutionized cancer treatment, it, unfortunately, does not spare cancer patients from possible immune-related adverse events (irAEs), which can also involve the peripheral nervous system. Immune checkpoint inhibitors (ICIs), blocking cytotoxic… read more here.
Keywords: checkpoint inhibitors; immune checkpoint; pns; marketing surveillance ... See more keywords
Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance.
Sign Up to like & getrecommendations! Published in 2021 at "Intestinal research"
DOI: 10.5217/ir.2021.00032
Abstract: Background/Aims Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in patients with UC in… read more here.
Keywords: week; analysis; safety; post marketing ... See more keywords